Valley Fever Solutions, Inc. (VFS, an Arizona corporation), is developing Nikkomycin Z (NikZ), first of a new class of antifungals, as a dramatically superior potential cure for Valley Fever, a painful and debilitating orphan disease causing over 2,000 serious cases and 150 deaths a year.
We recently were awarded funding to scale up the API drug substance manufacturing process. We expect a good quantity of bulk drug product in late February. We expect this will confirm a process for multi-kg scale runs as soon as support is available. We have tentative support for this scale up. Private funding would let us proceed as soon as funding is available.